Recommendations for the diagnosis and treatment of dense deposit disease.
Andrésdóttir
Margrét B
MB
Landspitali University Hospital, Reykjavik, Iceland. mband@landspitali.is
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D003131:Combined Modality Therapy; D017242:Complement Factor H / Q000235:genetics / Q000378:metabolism*; D003170:Complement Pathway, Alternative / Q000235:genetics; D004195:Disease Models, Animal; D018450:Disease Progression; D004502:Education, Medical, Continuing; D005260:Female; D005819:Genetic Markers / Q000235:genetics; D020022:Genetic Predisposition to Disease; D050533:Glomerular Basement Membrane / Q000473:pathology*; D015432:Glomerulonephritis, Membranoproliferative / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D006801:Humans; D007055:Iceland; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000628:therapy; D007677:Kidney Function Tests; D008297:Male; D010951:Plasma Exchange / Q000379:methods; D017410:Practice Guidelines as Topic; D011379:Prognosis; D018570:Risk Assessment; D000069283:Rituximab; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D005819:Genetic Markers; D000069283:Rituximab; D017242:Complement Factor H; C481642:eculizumab